8-K filed January 5, 2022, 6:59 PM ET ticker ANEB CIK 0001815974

leadership confidence high sentiment neutral materiality 0.55

Anebulo Pharmaceuticals names Simon Allen CEO effective Feb 1, 2022; Dr. Schneeberger resigns

Anebulo Pharmaceuticals, Inc.

Simon Allen appointed CEO and director, effective Feb 1, 2022; succeeds Daniel Schneeberger.
Dr. Schneeberger's resignation not due to any disagreement with company operations or policies.
Allen receives $450k base salary; stock options for 625k shares at $6.21 vesting quarterly over 4 years.
Allen eligible for $1.5M cash bonus if company sold for ≥$500M with Board approval.
Severance of 9 months base salary plus COBRA reimbursement for 12 months if terminated without cause.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Simon Allen

Member of the Board of Directors

ANEB · Anebulo Pharmaceuticals, Inc.

Effective: 2022-02-01
Filed: January 5, 2022, 6:59 PM ET

On January 3, 2022, Simon Allen was appointed to be our Chief Executive Officer and elected a member of our Board of Directors, both to be effective on February 1, 2022.

Departed

Daniel Schneeberger

Chief Executive Officer

ANEB · Anebulo Pharmaceuticals, Inc.

Effective: 2022-02-01
Successor: Simon Allen
Filed: January 5, 2022, 6:59 PM ET

Daniel Schneeberger, M.D. resigned such positions in order to bring in Mr. Allen.

Departed

Daniel Schneeberger

Director

ANEB · Anebulo Pharmaceuticals, Inc.

Effective: 2022-02-01
Successor: Simon Allen
Filed: January 5, 2022, 6:59 PM ET

Daniel Schneeberger, M.D. resigned such positions in order to bring in Mr. Allen.

Appointed

Simon Allen

Chief Executive Officer

ANEB · Anebulo Pharmaceuticals, Inc.

Effective: 2022-02-01
Filed: January 5, 2022, 6:59 PM ET

On January 3, 2022, Simon Allen was appointed to be our Chief Executive Officer and elected a member of our Board of Directors, both to be effective on February 1, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Simon Allen was elected as Member of the Board of Directors at Anebulo Pharmaceuticals, Inc..

Action: elected
Role: Member of the Board of Directors

Exact text from the filing

On January 3, 2022, Simon Allen was appointed to be our Chief Executive Officer and elected a member of our Board of Directors, both to be effective on February 1, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Schneeberger resigned as Chief Executive Officer at Anebulo Pharmaceuticals, Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

Daniel Schneeberger, M.D. resigned such positions in order to bring in Mr. Allen.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Schneeberger resigned as Director at Anebulo Pharmaceuticals, Inc..

Action: resigned
Role: Director

Exact text from the filing

Daniel Schneeberger, M.D. resigned such positions in order to bring in Mr. Allen.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Simon Allen was appointed as Chief Executive Officer at Anebulo Pharmaceuticals, Inc..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On January 3, 2022, Simon Allen was appointed to be our Chief Executive Officer and elected a member of our Board of Directors, both to be effective on February 1, 2022.

View on SEC.gov

Anebulo Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-000406

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.